drugset / Trial / NCT00032734

Efficacy of SR121463B in Patients With Syndrome of Inappropriate Antidiuretic Hormone Secretion

NCT00032734 ↗

Phase 2 Completed 35 enrolled Sanofi
RandomizedParallel-groupDouble-blindTreatment

Summary

The study is designed to assess the efficacy of an investigational drug called SR121463B (vasopressin receptor antagonist) in the treatment of low levels of sodium in the blood associated with the Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH). This double blind period study is followed by 2 open label extension studies with flexible doses of satavaptan.

Timeline

Start
2001-06
Primary completion
—
Completion
2003-07

Drugs

EvaluationDrugModalityDoseRoute
Subject satavaptan Small molecule — Oral